Niagen Bioscience (FRA:OCD1) Total Payout Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OCD1 Niagen Bioscience Inc FRA:OCD1
68 GF Score
Price €2.60
GF Value €3.77
! 2 Warning Signs
View Full Analysis

What is Niagen Bioscience Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Niagen Bioscience's current Total Payout Ratio is .

Niagen Bioscience Total Payout Ratio Related Terms

Niagen Bioscience Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Niagen Bioscience's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niagen Bioscience Total Payout Ratio Chart

Niagen Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Niagen Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:OCD1 vs CAMP, ALEC, ELDN: Total Payout Ratio Comparison

For the Packaged Foods subindustry, Niagen Bioscience's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Niagen Bioscience Total Payout Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Niagen Bioscience's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Niagen Bioscience's Total Payout Ratio falls into.


FRA:OCD1
68GF Score
Niagen Bioscience Inc FRA:OCD1
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niagen Bioscience Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Niagen Bioscience's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0.22240377801868 + 6.4204692251927 + -0) / 15.401683145501
=-0.40

Niagen Bioscience's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-2.3922763268114 + 0.23968563493 + -0) / 0.82823771302926
=2.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?

Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued. The current stock price of €2.60 is trading 31% below its estimated GF Value™ of €3.77.

Key valuation signals for FRA:OCD1:

  • Total Payout Ratio:
  • GF Value™: €3.77 vs. price of €2.60 (31% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Niagen Bioscience Business Description

Other Exchanges NAGE:USAOCD1:Germany
Address 10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
68GF Score

Get the complete analysis for FRA:OCD1

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.60
Price
€3.77
GF Value